Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celera Genomics (CRA) -- Ignore unavailable to you. Want to Upgrade?

To: Ilaine who wrote (161)	3/14/2000 10:37:00 PM
From: Rob Pierce	Read Replies (1) \| Respond to of 746

Actually, based on the article it seems that Venter was accurate about his final expectations of a filing for a few hundred (full) patents. His error seems to be in not being expressly clear at the time that the process will invlove filing a significantly larger body of >provisional< patent applications that will eventually reduce to his stated expectaions. He may be technically correct in his statement, but yes, he certainly left the door open for misinterpretation, and thus the resulting criticism. If this is but one in a series of ... inaccuracies(?) ... then I'm surprised that he and the company haven't been slammed any more seriously before now for lack of credibility. On a separate point, I understand how you can patent a process (say, a means to manipulate a gene), but I don't understand patenting the gene itself. Are Celera (and HGSI?) actually doing/intending to do the former rather than the latter?? RP